Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study
Open Access
- 18 May 2022
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 24 (8) , 1429-1438
Abstract
Aim: To evaluate the effect of canagliflozin, a sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor, on albuminuria and the decline of estimated glomerular filtration rate (eGFR) in participants with type 2 diabetes and microalbuminuria. Methods: The CANPIONE study is a multicentre, randomized, parallel‐group and open‐labelled study consisting of a unique 24‐week preintervention period, during which the rate of eGFR decline before intervention is estimated, followed by a 52‐week intervention and a 4‐week washout period. Participants with a geometric mean urinary albumin‐to‐creatinine ratio (UACR) of 50 and higher and less than 300 mg/g in two consecutive first‐morning voids at two different time points, and an eGFR of 45 ml/min/1.73m 2 or higher, are randomly assigned to receive canagliflozin 100 mg daily or to continue guideline‐recommended treatment, except for SGLT2 inhibitors. The first primary outcome is the change in UACR, and the second primary outcome is the change in eGFR slope. Results: A total of 258 participants were screened and 98 were randomized at 21 sites in Japan from August 2018 to May 2021. The mean baseline age was 61.4 years and 25.8% were female. The mean HbA1c was 7.9%, mean eGFR was 74.1 ml/min/1.73m 2 and median UACR was 104.2 mg/g. Conclusions: The CANPIONE study will determine whether the SGLT2 inhibitor canagliflozin can reduce albuminuria and slow eGFR decline in participants with type 2 diabetes and microalbuminuria.Keywords
Funding Information
- Mitsubishi Tanabe Pharma Corporation
This publication has 33 references indexed in Scilit:
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes MellitusCirculation, 2014
- Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)Cardiovascular Diabetology, 2014
- Chapter 1: Definition and classification of CKDKidney International Supplements, 2013
- Revised Equations for Estimated GFR From Serum Creatinine in JapanAmerican Journal of Kidney Diseases, 2009
- Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)Kidney International, 2003
- PLANNING AND REVISING THE SAMPLE SIZE FOR A TRIALStatistics in Medicine, 1995
- Interim analyses for monitoring clinical trials that do not materially affect the type I error rateStatistics in Medicine, 1992
- Sample size re-estimation without unblinding for normally distributed outcomes with unknown varianceCommunications in Statistics - Theory and Methods, 1992
- Etiology and Prognostic Significance of Albuminuria in DiabetesDiabetes Care, 1988
- Diabetic Nephropathy and Arterial Hypertension: The Effect of Antihypertensive TreatmentDiabetes, 1983